Advances in SARS-CoV-2 humoral immune response mechanism and antibody detection techniques

LIU Yinuo; SHI Yonglin

doi:10.19837/j.cnki.ahyf.2024.06.012

PDF(821 KB)

Anhui Journal of Preventive Medicine ›› 2024, Vol. 30 ›› Issue (6) : 484-489. DOI: 10.19837/j.cnki.ahyf.2024.06.012

Review

Advances in SARS-CoV-2 humoral immune response mechanism and antibody detection techniques

LIU Yinuo¹, SHI Yonglin^1,2

Author information +

History +

Abstract

In recent years,SARS-CoV-2 has become a public health emergency of international concern due to its high mutation rate,and the COVID-19 pandemic has become a public health emergency of international concern.In this paper,we review the pathogenetic characteristics of SARS-CoV-2,the characteristics of humoral immune response to SARS-CoV-2,the humoral immune response to SARS-CoV-2 after natural infection and vaccination,and the application of SARS-CoV-2 antibody detection technology,in order to provide scientific basis for vaccine research and development,and the formulation of public health policies.

Key words

SARS-CoV-2 / Antibody testing / Immune protection

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIU Yinuo, SHI Yonglin. Advances in SARS-CoV-2 humoral immune response mechanism and antibody detection techniques[J]. Anhui Journal of Preventive Medicine. 2024, 30(6): 484-489 https://doi.org/10.19837/j.cnki.ahyf.2024.06.012

References

[1] Abbasian MH,Mahmanzar M,Rahimian K,et al.Global landscape of SARS-CoV-2 mutations and conserved regions[J].J Transl Med,2023,21(1):152.
[2] Geanes ES,McLennan R,LeMaster C,et al.Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity[J].Commun Med,2024,4(1):47.
[3] McCallum M,Walls AC,Bowen JE,et al.Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation[J].Nat Struct Mol Biol,2020,27(10):942-949.
[4] Mohamadian M,Chiti H,Shoghli A,et al.COVID-19:Virology,biology and novel laboratory diagnosis[J].J Gene Med,2021,23(2):e3303.
[5] V’Kovski P,Kratzel A,Steiner S,et al.Coronavirus biology and replication:implications for SARS-CoV-2[J].Nat Rev Microbiol,2021,19(3):155-170.
[6] Ju B,Zhang Q,Ge J,et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection[J].Nature,2020,584(7819):115-119.
[7] Zhou P,Yang XL,Wang XG,et al.Addendum:a pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020,588(7836):E6.
[8] 徐宝丽,管甲亮,术超,等.新型冠状病毒COVID-19相关研究进展[J].中华医院感染学杂志,2020,30(6):839-844.
[9] Matinfar S,Mortezagholi S,Amiri D,et al.Investigating the seroconversion patterns of specific antibodies against various antigens of SARS-CoV-2 in hospitalized COVID-19 patients and vaccinated individuals[J].Arch Clin Infect Dis,2024,19(1):e140414.
[10] 吴雯,周贵香,施超,等.新型冠状病毒感染者特异性抗体变化特征分析[J].中国公共卫生,2022,38(6):804-807.
[11] 宋云,毋碧聪,卢世栋,等.新型冠状病毒肺炎患者血清IgM和IgG抗体动态变化分析[J].中华微生物学和免疫学杂志,2021,41(6):417-422.
[12] Zhao Z,Kumanovics A,Love T,et al.T cell responses correlate with self-reported disease severity and neutralizing antibody responses predict protection against SARS-CoV-2 breakthrough infection[J].Viruses,2023,15(3):709.
[13] Kumar A,Tripathi P,Kumar P,et al.From detection to protection:antibodies and their crucial role in diagnosing and combatting SARS-CoV-2[J].Vaccines,2024,12(5):459.
[14] 石慧春,焦凡珂,徐巍,等.靶向SARS-CoV-2受体结合结构域的嵌合抗体表达及功能研究[J].微生物与感染,2023,18(1):2-12.
[15] Xue JB,Tao SC.Epitope analysis of anti-SARS-CoV-2 neutralizing antibodies[J].Curr Med Sci,2021,41(6):1065-1074.
[16] 徐婧玥.新型冠状病毒抗体检测及应用[J].华北理工大学学报(医学版),2022,24(4):331-336.
[17] Chen X,Pan Z,Yue S,et al.Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19[J].Signal Transduct Target Ther,2020,5(1):180.
[18] Gaebler C,Wang Z,Lorenzi JCC,et al.Evolution of antibody immunity to SARS-CoV-2[J].Nature,2021,591(7851):639-644.
[19] Wajnberg A,Amanat F,Firpo A,et al.Robust neutralizing antibodies to SARS-CoV-2 infection persist for months[J].Science,2020,370(6521):1227-1230.
[20] 郭楠,姚雅萍,宋乐,等.新型冠状病毒感染后特异性抗体的动态变化[J].解放军医学院学报,2023,44(12):1344-1350.
[21] Feng C,Shi J,Fan Q,et al.Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery[J].Nat Commun,2021,12(1):4984.
[22] Li X,Yin Y,Pang L,et al.Colloidal gold immunochromatographic assay (GICA) is an effective screening method for identifying detectable anti-SARS-CoV-2 neutralizing antibodies[J].Int J Infect Dis,2021,108:483-486.
[23] 李幸乐,卢世栋,李金月,等.新型冠状病毒肺炎病例血清中和抗体动态变化及影响因素[J].中华实验和临床病毒学杂志,2021,35(3):341-344.
[24] Garcia-Beltran WF,Lam EC,St Denis K,et al.Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity[J].Cell,2021,184(9):2523.
[25] Luo WR,Wu XM,Wang W,et al.Novel coronavirus mutations:vaccine development and challenges[J].Microb Pathog,2022,173(Pt A):105828.
[26] 杨燕,王慧娟,黄保英,等.376例新冠肺炎恢复期与灭活疫苗接种后人群的血清抗体检测结果分析[J].国际病毒学杂志,2022,29(4):315-319.
[27] Szczepanek J,Skorupa M,Jarkiewicz-Tretyn J,et al.COVID-19 vaccination in healthcare workers:long-term benefits and protection[J].Cent Eur J Immunol,2023,48(4):311-321.
[28] Narowski TM,Raphel K,Adams LE,et al.SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people[J].Cell Rep,2022,38(5):110336.
[29] Schest S,Langer C,Stiegler Y,et al.Vaccine-induced SARS-CoV-2 antibody response:the comparability of S1-specific binding assays depends on epitope and isotype discrimination[J].Front Immunol,2023,14:1257265.
[30] Liu J,Yan W,Liu Z,et al.A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination[J].Med Nov Technol Devices,2021,11:100084.
[31] Díaz-Dinamarca DA,Díaz P,Barra G,et al.Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile[J].Front Public Health,2023,11:1229045.
[32] Anichini G,Terrosi C,Gori Savellini G,et al.Neutralizing antibody response of vaccinees to SARS-CoV-2 variants[J].Vaccines,2021,9(5):517.
[33] Karachaliou M,Moncunill G,Espinosa A,et al.SARS-CoV-2 infection,vaccination,and antibody response trajectories in adults:a cohort study in Catalonia[J].BMC Med,2022,20(1):347.
[34] 何军,罗婉蓉,夏艺丹,等.新型冠状病毒变异株的演化与研究进展[J].安徽预防医学杂志,2023,29(4):317-323+331.
[35] McDade TW,Sancilio A.Beyond serosurveys:human biology and the measurement of SARS-Cov-2 antibodies[J].Am J Hum Biol,2020,32(5):e23483.
[36] Zahirul Islam ZH.Comparison of rapid SARS- cov-2 antigen detection assay with real-time RT-PCR assay[J].Biomed J Sci Tech Res,2024,55(1):46549-46555.
[37] Muller DA,Depelsenaire AC,Young PR.Clinical and laboratory diagnosis of dengue virus infection[J].J Infect Dis,2017,215(suppl_2):S89-S95.
[38] Hosseini S,Vázquez-Villegas P,Rito-Palomares M,et al.Advantages,disadvantages and modifications of conventional ELISA[J].Enzyme-Linked Immunosorbent Assay (ELISA) from A to Z,2018:67-115.
[39] Hayrapetyan H,Tran T,Tellez-Corrales E,et al.Enzyme-linked immunosorbent assay:types and applications[J].Methods Mol Biol,2023,2612:1-17.
[40] Liu PP,Zong Y,Jiang SP,et al.Development of a nucleocapsid protein-based ELISA for detection of human IgM and IgG antibodies to SARS-CoV-2[J].ACS Omega,2021,6(14):9667-9671.
[41] Cinquanta L,Fontana DE,Bizzaro N.Chemiluminescent immunoassay technology:what does it change in autoantibody detection?[J].Auto Immun Highlights,2017,8(1):9.
[42] Wang C,Wu J,Zong C,et al.Chemiluminescent immunoassay and its applications[J].Chin J Anal Chem,2012,40(1):3-10.
[43] Ye L,Xu X,Song S,et al.Rapid colloidal gold immunochromatographic assay for the detection of SARS-CoV-2 total antibodies after vaccination[J].J Mater Chem B,2022,10(11):1786-1794.
[44] Ye L,Lei X,Xu L,et al.Gold nanoparticle-based immunochromatographic assay for the rapid detection of the SARS-CoV-2 Omicron variant[J].Mater Chem Front,2023,7(18):4063-4072.
[45] Frische A,Brooks PT,Gybel-Brask M,et al.Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay[J].PLoS One,2022,17(7):e0272298.
[46] Liu KT,Han YJ,Wu GH,et al.Overview of neutralization assays and international standard for detecting SARS-CoV-2 neutralizing antibody[J].Viruses,2022,14(7):1560.
[47] Sun Y,Huang W,Xiang H,et al.SARS-CoV-2 neutralization assays used in clinical trials:a narrative review[J].Vaccines,2024,12(5):554.
[48] 胡燕,申鸽,李琼,等.2种SARS-CoV-2抗体检测方法在COVID-19诊断中的价值[J].检验医学,2020,35(12):1294-1297.
[49] 李芳彩,戴志辉,贺子翔,等.ELISA法与胶体金法在检测新型冠状病毒血清抗体中的应用探讨[J].实用预防医学,2020,27(7):780-783.
[50] Shen B,Zheng Y,Zhang X,et al.Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG[J].Am J Transl Res,2020,12(4):1348-1354.
[51] 陈维欣,陈萌,周珊珊,等.新型冠状病毒疫苗免疫后抗体水平检测的3种实验方法比较[J].中华微生物学和免疫学杂志,2021,41(6):423-426.
[52] Gilboa T,Cohen L,Cheng CA,et al.A SARS-CoV-2 neutralization assay using single molecule arrays[J].Angew Chem Int Ed,2021,60(49):25966-25972.
[53] Tan SS,Saw S,Chew KL,et al.Comparative clinical evaluation of the Roche elecsys and Abbott severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology assays for coronavirus disease 2019 (COVID-19)[J].Arch Pathol Lab Med,2021,145(1):32-38.